Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Monkey Pox Treatment Market Forecast Highlighting Growth From $0.11 Billion To $0.18 Billion
The market for monkeypox treatments has experienced substantial expansion lately, projected to increase from $0.1 billion in 2025 to $0.11 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. This recent growth trajectory builds upon factors observed during the historical period, including prior outbreaks in areas where the disease is endemic, insufficient vaccine availability, diagnostic delays stemming from a lack of public awareness, a primary reliance on palliative care measures, and the virus’s global dissemination during the 2022 outbreak.
The market for monkeypox treatments is poised for substantial expansion in the upcoming years, projected to reach $0.18 billion by 2030 with a compound annual growth rate of 13.0%. This projected growth is fueled by several key factors, including the advancement of antiviral drug pipelines, increased global vaccination efforts, elevated investment in infectious disease research, the utilization of enhanced diagnostic technologies, and the proliferation of government-led preparedness initiatives. During this forecast period, prominent market trends will encompass the development of more targeted antiviral therapies, the implementation of artificial intelligence for predicting outbreaks, the expansion of digital systems for monitoring cases, the greater integration of Internet of Things (IoT) technology in disease surveillance networks, and a growing demand for environmentally sustainable vaccine manufacturing methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18818&type=smp
Monkey Pox Treatment Market Growth Factors Supporting Long-Term Expansion
The monkeypox treatment market is anticipated to experience expansion due to the escalating incidence of zoonotic infections. These infections, which originate in animals and spread to humans via direct contact, contaminated settings, or carriers, are becoming more common. Heightened interaction between people and animals inherently escalates the danger of zoonotic disease transmission. Furthermore, the impacts of climate change exacerbate this peril by broadening the geographical distribution of disease carriers and introducing disease-causing agents into novel territories. Therapies for monkeypox are employed to manage the affliction by directly combating the virus and mitigating the signs and symptoms in affected individuals as well as potentially infected animals. Illustratively, data from the UK Health Security Agency, a governmental body in the United Kingdom, indicated 3,732 confirmed mpox instances in the UK as of August 2024, with an additional 21 cases reported in 2023, bringing the total to 3753. Consequently, the rising rate of zoonotic infections serves as a significant catalyst for the market’s growth in monkeypox treatments.
Monkey Pox Treatment Market Segmentation And Category Breakdown
The monkey pox treatment market covered in this report is segmented –
1) By Treatment Type: Prophylactic Vaccines, Therapeutics
2) By Dosage Forms: Solid, Liquid, Semi Solid
3) By Route Of Administration: Oral, Topical, Parenteral
4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Prophylactic Vaccines: Vaccinia-Based Vaccines, Modified Vaccinia Ankara (MVA) Vaccines
2) By Therapeutics: Antiviral Agents (Tecovirimat, Brincidofovir), Immune Modulators, Supportive Care Treatments
Monkey Pox Treatment Market Industry Trends Shaping Future Revenue Growth
The primary entities within the monkeypox treatment arena are presently engaged in the creation of pioneering treatments, specifically small-molecule antivirals, with the dual aims of bolstering international health readiness and augmenting stockpiling capabilities. These small-molecule antiviral agents function by impeding particular viral proteins, thereby interrupting the propagation of the virus throughout the body, and their capacity for prolonged storage renders them exceptionally suitable for emergency situations. Illustrating this point, in January of 2025, SIGA Technologies, a pharmaceutical firm based in the United States, achieved regulatory approval in Japan for TEPOXX, which consists of 200 mg capsules of tecovirimat, thereby establishing it as that nation’s inaugural antiviral medication designed to combat orthopoxviruses. Evidence from fifteen clinical investigations encompassing more than 800 healthy participants underscores the favorable safety profile of this medication, which also demonstrated measurable pharmacokinetic characteristics within effective dosage parameters and presented significant efficacy in preclinical animal studies, evidenced by reductions in both mortality rates and viral burden. The therapeutic mechanism of this drug involves the inhibition of the VP37 protein found on the exterior of the virus, which in turn impedes the release of the virus from infected cells, thereby facilitating the immune system’s ability to eradicate the infection. To facilitate the establishment of Japan’s strategic national reserve of TEPOXX, SIGA has entered into a collaboration with Japan Biotechno Pharma, appointing them as the exclusive distributor.
Monkey Pox Treatment Market Competitive Analysis Of Major Industry Participants
Major companies operating in the monkey pox treatment market are Merck & Co Inc, Sanofi S A, Gilead Sciences Inc, BioNTech SE, Moderna Inc, Novavax Inc, Emergent BioSolutions Inc, Bavarian Nordic A S, SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, Chimerix Inc, Emcure Pharmaceuticals Ltd, VBI Vaccines Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, GeoVax Labs Inc, Zydus Cadila Ltd, Serum Institute of India Pvt Ltd, Biological E Ltd, Dr Reddy’s Laboratories Ltd, Hester Bioscience Ltd, Indian Immunologicals Ltd, Reliance Life Sciences Pvt Ltd, Takeda Pharmaceuticals Co Ltd, KM Biologics Co Ltd, Meridian Bioscience Inc, NanoViricides Inc.
Access The Complete Monkey Pox Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report
Monkey Pox Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the monkey pox treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
